What Is Ipamorelin? Uses, Risks, and FDA Status
What Is Ipamorelin?
Ipamorelin is a synthetic growth hormone secretagogue — a pentapeptide (five amino acids) that stimulates the pituitary gland to release growth hormone. Developed in the late 1990s, it is considered one of the most selective growth hormone-releasing peptides (GHRPs) because it triggers GH release without significantly affecting cortisol or prolactin levels. This selectivity has made it one of the most popular peptides in anti-aging and performance optimization protocols.
How Does Ipamorelin Work?
Ipamorelin binds to the ghrelin receptor (GHS-R1a) in the pituitary gland, mimicking the action of ghrelin — the body's natural hunger and growth hormone-stimulating hormone. This binding triggers a pulsatile release of growth hormone that closely resembles the body's natural GH secretion pattern. Unlike other GHRPs such as GHRP-6 or GHRP-2, ipamorelin does not cause significant spikes in cortisol, ACTH, or prolactin at therapeutic doses (Raun et al., Eur J Endocrinol, 1998). This makes it a "cleaner" GH secretagogue with fewer off-target hormonal effects.
What Is Ipamorelin Used For?
Based on published research and clinical use, ipamorelin has been investigated for:
- Growth hormone optimization — Increasing natural GH output in adults with age-related GH decline
- Body composition — Research suggests improvements in lean muscle mass and reduction in body fat
- Recovery and repair — Enhanced tissue recovery through GH-mediated pathways
- Sleep quality — GH is primarily released during deep sleep; ipamorelin may support natural sleep-related GH pulses
- Bone density — GH plays a role in bone metabolism; preliminary data suggests potential benefits for bone health
- Anti-aging protocols — Commonly used in longevity-focused clinical settings
What Are the Risks?
- Water retention. Mild fluid retention is commonly reported, particularly in the initial weeks of use.
- Headaches. Some users report transient headaches, especially at higher doses.
- Injection site reactions. Redness or irritation at the injection site.
- Potential for GH-related side effects. Prolonged elevation of growth hormone can theoretically contribute to joint pain, carpal tunnel symptoms, or insulin resistance, though these are more commonly associated with exogenous GH than with secretagogues.
- Limited long-term data. While ipamorelin has been used clinically for years, large-scale long-term safety studies are lacking.
- Contraindicated in active cancer. Growth hormone stimulation is generally contraindicated in individuals with active malignancies.
FDA Status
Ipamorelin was reclassified from Category 2 to Category 1 by the FDA in February 2026 as part of the broader 14-peptide reclassification. This means licensed compounding pharmacies can legally prepare ipamorelin with a physician prescription. It is not FDA-approved as a standalone drug. It is frequently compounded in combination with CJC-1295 (another GH-releasing peptide) for synergistic effects.
Key Takeaway
Ipamorelin is a selective growth hormone secretagogue with a favorable side effect profile, now legally available through licensed compounding pharmacies under physician supervision.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.